Análisis de la acción Bionano Genomics, Inc. (BNGO)BNGOBionano Genomics, Inc.

Bionano Genomics, Inc. is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company offers optical genome mapping (OGM) solutions for applications across basic, translational and clinical research. It also offers a platform-agnostic software solution, which integrates sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants, and absence of heterozygosity across the genome in one consolidated view. The Company additionally offers nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. The Company markets and sells OGM systems, including the Saphyr system, which delivers OGM data to enable ultra-sensitive and ultra-specific detection of all classes of structural variation (SV). It operates in the Healthcare sector (LABORATORY ANALYTICAL INSTRUMENTS industry).

Bionano Genomics Inc is not a strong buy at the current price of $1.17, given its RSI of 38.471 indicating oversold conditions, and the significant 71.39% decline over the past year. The company shows potential with a projected trajectory change of +104.29% based on historical patterns, but risks remain due to a high net loss of -7.42 million in Q2 2026 and ongoing challenges in software revenue.

2 analysts cover BNGO: 2 rate it Buy, 0 Hold and 0 Sell. The average price target is 7.50.